Recon: Trump Tariffs Target China-Made Drug Ingredients

• Trump Tariffs Target Key Ingredients for Dozens of Drugs (Bloomberg) (AAM) (NYT) (Fox News) (Law360-$) (BioPharma Dive)
• Will the Trump tariffs on China raise drug prices for Americans? (STAT-$) (Axios)
• Eli Lilly ponies up $63M for Sigilon’s diabetes cell therapies (Fierce) (Endpoints) (The Pharma Letter) (Boston Business Journal-$)
• Terns emerges with all 3 of Lilly’s NASH programs and $30M from Lilly Asia Ventures (Fierce) (Endpoints)
• Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup (Endpoints) (Fierce)
• On the heels of major Pfizer deal, Arvinas snags $55M Series C for protein degradation cancer programs (Endpoints) (Fierce)
• Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price: Sources (CNBC) (Reuters) (Fierce)
• Unusual forms of 'nightmare' antibiotic-resistant bacteria detected in 27 states (CNN) (Fox News) (Axios) (Fortune) (Scientific American)
• Ohio regulator orders insurers, benefit managers to give lowest drug price (Reuters) (The Columbus Dispatch) 

• Sofinnova raises €275M crossover fund to back late-stage firms (Fierce) (Endpoints)
• Kymera pens new pact with GSK as protein degradation R&D continues to ramp up (Fierce) (The Pharma Letter)
• Exclusive - Hospital contract disarray highlights challenges to Saudi healthcare reform (Reuters)
• To be a global player, China plays by global standards (The Pharma Letter-$)
• US may revoke special tariff if India continues pricing control on medical devices (Economic Times)

• Benefit of GenSight's gene therapy not so clear (BioPharma Dive) (Endpoints)
• Déjà vu? PhRMA rolls drug cost ads, insurers push back—this time on costly coupon rules (Fierce)
• How long are delays in cancer drug approvals outside the U.S.? (Drug Channels)
• Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks (Fierce)
• Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report (Fierce)
• Agilent pays $105 million to acquire DNA firm Lasergen (The Pharma Letter-$) (Press)
• Volatility returns for big biopharma (EP Vantage

• Genomic analysis uncovers prevalence of RNA splicing mutations in 33 tumor types (Fierce)
• NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic (NIH)
• How CRISPR works, explained in two minutes (STAT)
• Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors (Press)
• Cancer researchers push to relax rules for clinical trials (Nature)
• Allergan notches third trial success for depression drug (BioPharma Dive)

• CVS Health eyes kidney patients for next expansion into care (ABC News)
• MIT Ends Contract With Nectome, the 100% Fatal Brain Freeze Startup (Fortune)
• Genomics Is on the Rise (MedPage Today)
• Siemens wins FDA nod for Somatom Edge plus CT scanner (MassDevice)
• Curetis wins FDA nod for respiratory infection diagnostic system (Drug Delivery Business News)
• Boomers line up for joint replacements, and their expectations are high (STAT-$)
• Nvidia's Project Clara Medical Imaging Supercomputer Will Speed Up Detection Of Deadly Diseases (Forbes)

• Planned Parenthood President Cecile Richards: Jared Kushner and Ivanka Trump offered a 'bribe' to stop abortions (CNBC)
• Amazon could do a lot to fix the U.S. health-care system — but Walmart could do more (CNBC)
• Taxpayers bore the brunt of Trump’s ACA changes (Axios)
• The politics of ACA rate hikes will be 2016 in reverse (Axios)
• How Studying Sewage May Help Slow the Opioid Epidemic (Fortune)
• U.S. Obamacare 2018 exchange enrollment drops 3 percent: CMS (Reuters)
• Lab animal regulations can be simplified without weakening welfare standards (STAT)
• Why Private Equity Loves Retail Healthcare (Forbes)

• FDA Advisory Committee Calendar

• BiondVax preps for phase 3 universal flu vaccine trial in Europe (Fierce)
• MA granted for drug tested in just 34 patients (The Pharma Letter-$)
• Russia to start exports of innovative polio vaccine (The Pharma Letter-$)
• Collaboration formed for development of novel IgE antibodies (EPM Magazine)
• Field Safety Notice - 26 to 30 March 2018 (MHRA)
• Abiomed wins CE Mark for Impella 5.5 (MassDevice) (Press)
• EPO fee reduction takes effect as of 1 April 2018 (EPO)

• Prioritise universal health coverage, healthier populations create more productive economies: WHO (Business Standard)
• Curetis’ Unyvero BCU Blood Culture Application Receives Approval from Singapore Health Sciences Authority (Press)
• SARS-like outbreak among pigs rekindles concerns virus could again strike humans (STAT-$)
• South Korea has a sting in the tail for drinkers who mix wasps and soju (Channel NewsAsia)

• Glenmark gets license to market Akynzeo in India (The Pharma Letter-$)
• India waking up to a malnutrition crisis and its dire consequences (Qrius)
• CDSCO move to choose notified bodies for medical devices hits wall as low fee structure drives away firms (pharmabiz)

• Aussie Gets 10 Years For 'Largest Ever' Tax Fraud Case (Law360-$)
• Big pharma under fire for spruiking strong painkillers to doctors (Brisbane Times)
• Riverside sells Australian health care business (Crain’s Cleveland Business)
• Labor pushed to explain rebate cut on ‘junk’ policies (The Australian)

• B.C. targets private health care with new penalties for extra billing (The Globe and Mail)
• Glycovax Pharma Files a Patent Application for a New Semi-Synthetic Vaccine against Breast Cancers (Press)
• Drug company knew Oxycontin was addictive and lied about it, says plaintiff in class action suit (CBC News)

• Health systems overlook potential of real estate assets (Modern Healthcare)
• Smartphone app might offer new way to measure blood flow (Reuters) (Science Daily) (The Tribune)